JP6550388B2 - 神経変性疾患の治療 - Google Patents
神経変性疾患の治療 Download PDFInfo
- Publication number
- JP6550388B2 JP6550388B2 JP2016539206A JP2016539206A JP6550388B2 JP 6550388 B2 JP6550388 B2 JP 6550388B2 JP 2016539206 A JP2016539206 A JP 2016539206A JP 2016539206 A JP2016539206 A JP 2016539206A JP 6550388 B2 JP6550388 B2 JP 6550388B2
- Authority
- JP
- Japan
- Prior art keywords
- laccer
- b4galt6
- subject
- level
- astrocytes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/285—Demyelinating diseases; Multipel sclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pathology (AREA)
- Rehabilitation Therapy (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Neurology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361963738P | 2013-12-12 | 2013-12-12 | |
| US61/963,738 | 2013-12-12 | ||
| US201462049813P | 2014-09-12 | 2014-09-12 | |
| US62/049,813 | 2014-09-12 | ||
| PCT/US2014/070099 WO2015089443A2 (en) | 2013-12-12 | 2014-12-12 | Treating neurodegenerative disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017502278A JP2017502278A (ja) | 2017-01-19 |
| JP2017502278A5 JP2017502278A5 (enExample) | 2018-02-01 |
| JP6550388B2 true JP6550388B2 (ja) | 2019-07-24 |
Family
ID=53371971
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016539206A Expired - Fee Related JP6550388B2 (ja) | 2013-12-12 | 2014-12-12 | 神経変性疾患の治療 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9927437B2 (enExample) |
| EP (1) | EP3080602B1 (enExample) |
| JP (1) | JP6550388B2 (enExample) |
| KR (1) | KR20160089528A (enExample) |
| CN (1) | CN106030302B (enExample) |
| CA (1) | CA2933554A1 (enExample) |
| WO (1) | WO2015089443A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10512656B2 (en) | 2016-04-21 | 2019-12-24 | Baylor College Of Medicine | Compositions and methods for the treatment of lysosomal storage disorders and disorders characterized by lysosomal dysfunction |
| JP7084689B2 (ja) * | 2016-12-08 | 2022-06-15 | 公益財団法人東京都医学総合研究所 | 脳組織の異常を伴う非ヒト動物の作製方法およびその利用 |
| US20200197366A1 (en) * | 2017-08-08 | 2020-06-25 | Kashiv Biosciences, Llc | Pharmaceutical composition comprising eliglustat |
| JP2021515037A (ja) | 2018-02-26 | 2021-06-17 | アントルクス,インコーポレーテッド | 寛容原性リポソーム及びその使用方法 |
| WO2019169317A1 (en) * | 2018-03-02 | 2019-09-06 | Stueve Olaf | Methods and compositions for treating natalizumab-associated progressive multifocal encephalopathy |
| AU2019344006B2 (en) | 2018-09-21 | 2025-11-27 | University Of Connecticut | Compositions and methods to restore paternal UBE3A gene expression in human Angelman Syndrome |
| CN114717232A (zh) * | 2020-12-22 | 2022-07-08 | 未来智人再生医学研究院(广州)有限公司 | 表达irf-1靶向抑制因子的多能干细胞及其衍生物与应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5700909A (en) * | 1993-07-30 | 1997-12-23 | The Regents Of The University Of California | Prosaposin and cytokine-derived peptides |
| EP1825853A2 (en) | 1998-07-27 | 2007-08-29 | Johns Hopkins University | Methods for treating conditions modulated by lactosyceramide |
| JP2007516294A (ja) * | 2003-12-23 | 2007-06-21 | エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント | 炎症性の疾患または症状の予防および治療のための方法および組成物 |
| FR2869915B1 (fr) * | 2004-05-07 | 2006-08-18 | Merck Sante Soc Par Actions Si | Gm3 synthase, comme cible therapeutique dans les complications microvasculaires du diabete |
| US20090111812A1 (en) * | 2004-06-14 | 2009-04-30 | Musc Foundation For Research Development | Methods for treating inflammatory disorders |
| US7572592B2 (en) * | 2005-01-31 | 2009-08-11 | Glycominds Ltd | Method for diagnosing multiple sclerosis |
| US8263576B2 (en) * | 2006-08-15 | 2012-09-11 | Mayo Foundation For Medical Education And Research | Non-natural sphingolipid analogs and uses thereof |
| AU2009315230A1 (en) * | 2008-11-12 | 2010-05-20 | The Brigham And Women's Hospital, Inc. | Diagnosis of multiple sclerosis |
| AU2011329681A1 (en) * | 2010-11-18 | 2013-05-30 | Synta Pharmaceuticals Corp. | Preselection of subjects for therapeutic treatment based on hypoxic status |
| WO2012088133A1 (en) * | 2010-12-20 | 2012-06-28 | Stephen Davies | Methods for treating neurological conditions and compositions and materials therefor |
| CN102994554A (zh) * | 2011-09-15 | 2013-03-27 | 花王株式会社 | 神经酰胺和/或葡萄糖神经酰胺产生促进剂的制造方法 |
| CN103059160B (zh) * | 2011-10-20 | 2015-12-02 | 中国科学院上海药物研究所 | β-葡聚糖GFPBW1及其制备方法和用途 |
-
2014
- 2014-12-12 CN CN201480075396.4A patent/CN106030302B/zh active Active
- 2014-12-12 CA CA2933554A patent/CA2933554A1/en not_active Abandoned
- 2014-12-12 JP JP2016539206A patent/JP6550388B2/ja not_active Expired - Fee Related
- 2014-12-12 WO PCT/US2014/070099 patent/WO2015089443A2/en not_active Ceased
- 2014-12-12 KR KR1020167018593A patent/KR20160089528A/ko not_active Abandoned
- 2014-12-12 EP EP14868919.3A patent/EP3080602B1/en active Active
- 2014-12-12 US US15/103,632 patent/US9927437B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015089443A3 (en) | 2015-11-12 |
| WO2015089443A2 (en) | 2015-06-18 |
| CA2933554A1 (en) | 2015-06-18 |
| CN106030302B (zh) | 2019-09-24 |
| JP2017502278A (ja) | 2017-01-19 |
| CN106030302A (zh) | 2016-10-12 |
| EP3080602A4 (en) | 2017-07-05 |
| KR20160089528A (ko) | 2016-07-27 |
| US9927437B2 (en) | 2018-03-27 |
| EP3080602B1 (en) | 2018-11-28 |
| US20160313324A1 (en) | 2016-10-27 |
| EP3080602A2 (en) | 2016-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6550388B2 (ja) | 神経変性疾患の治療 | |
| Kwon et al. | SGK1 inhibition in glia ameliorates pathologies and symptoms in Parkinson disease animal models | |
| Shi et al. | Treg cell-derived osteopontin promotes microglia-mediated white matter repair after ischemic stroke | |
| US9248128B2 (en) | Method for enhancing remyelination using GLI1 inhibitors | |
| Cacabelos et al. | Neuroimmune crosstalk in CNS disorders: the histamine connection | |
| Smith et al. | The impact of regional astrocyte interferon-γ signaling during chronic autoimmunity: a novel role for the immunoproteasome | |
| CA3127452A1 (en) | In vitro human blood brain barrier | |
| De Vito et al. | MiR‐142‐3p regulates synaptopathy‐driven disease progression in multiple sclerosis | |
| Ulrich et al. | Machine learning approach identifies new pathways associated with demyelination in a viral model of multiple sclerosis | |
| Choi et al. | DSCR 1‐mediated TET 1 splicing regulates miR‐124 expression to control adult hippocampal neurogenesis | |
| Zhan et al. | A DEAD‐box RNA helicase Ddx54 protein in oligodendrocytes is indispensable for myelination in the central nervous system | |
| Liu et al. | Atsttrin reduces lipopolysaccharide-induced neuroinflammation by inhibiting the nuclear factor kappa B signaling pathway | |
| Mayo et al. | B4GALT6 regulates astrocyte activation during CNS inflammation | |
| US9139879B2 (en) | TAM receptors and TAM receptor ligands in detection and modulation of neuropathological disease | |
| US20250152711A1 (en) | Compositions and methods for modulating the immune system | |
| HK1230277B (en) | Treating neurodegenerative disease | |
| HK1230277A1 (en) | Treating neurodegenerative disease | |
| US11946046B2 (en) | Staufen1 regulating agents and associated methods | |
| CN102370981B (zh) | 防治神经退行性疾病的试剂和方法 | |
| Zhang et al. | Microglial repopulation alleviates surgery‐induced neuroinflammation and cognitive impairment in a ZEB1‐dependent manner | |
| Dejbakht et al. | Multiple Sclerosis: New Insights into Molecular Pathogenesis and Novel Platforms for Disease Treatment | |
| EP4076429A1 (en) | Compositions and methods for treating neuromuscular disorders | |
| Goins et al. | Neuroimmune mechanisms of a mouse model of chronic back pain | |
| US20240263237A1 (en) | T cell transcriptomic profiles in parkinson's disease, and methods and uses thereof | |
| Krzak | Microglial succinate receptor 1 (SUCNR1) sustains chronic CNS inflammation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171212 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20171212 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20180921 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20181030 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190130 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190618 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190701 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6550388 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |